Cargando…
Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study
BACKGROUND: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients. METHODS: Hospitalized patients with acute dete...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923183/ https://www.ncbi.nlm.nih.gov/pubmed/36793753 http://dx.doi.org/10.1016/j.lanwpc.2022.100638 |
_version_ | 1784887682854289408 |
---|---|
author | Li, Peng Liang, Xi Luo, Jinjin Li, Jiaqi Xin, Jiaojiao Jiang, Jing Shi, Dongyan Lu, Yingyan Hassan, Hozeifa Mohamed Zhou, Qian Hao, Shaorui Zhang, Huafen Wu, Tianzhou Li, Tan Yao, Heng Ren, Keke Guo, Beibei Zhou, Xingping Chen, Jiaxian He, Lulu Yang, Hui Hu, Wen Ma, Shiwen Li, Bingqi You, Shaoli Xin, Shaojie Chen, Yu Li, Jun |
author_facet | Li, Peng Liang, Xi Luo, Jinjin Li, Jiaqi Xin, Jiaojiao Jiang, Jing Shi, Dongyan Lu, Yingyan Hassan, Hozeifa Mohamed Zhou, Qian Hao, Shaorui Zhang, Huafen Wu, Tianzhou Li, Tan Yao, Heng Ren, Keke Guo, Beibei Zhou, Xingping Chen, Jiaxian He, Lulu Yang, Hui Hu, Wen Ma, Shiwen Li, Bingqi You, Shaoli Xin, Shaojie Chen, Yu Li, Jun |
author_sort | Li, Peng |
collection | PubMed |
description | BACKGROUND: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients. METHODS: Hospitalized patients with acute deterioration of HBV-related chronic liver disease (n = 4577) from the Chinese Group on the Study of Severe Hepatitis B (COSSH) open cohort were enrolled to evaluate the performance of five commonly used scores for predicting the prognosis and transplant survival benefit. The survival benefit rate was calculated to reflect the extended rate of the expected lifetime with vs. without LT. FINDINGS: In total, 368 HBV-ACLF patients received LT. They showed significantly higher 1-year survival than those on the waitlist in both the entire HBV-ACLF cohort (77.2%/52.3%, p < 0.001) and the propensity score matching cohort (77.2%/27.6%, p < 0.001). The area under the receiver operating characteristic curve (AUROC) showed that the COSSH-ACLF II score performed best (AUROC 0.849) at identifying the 1-year risk of death on the waitlist and best (AUROC 0.864) at predicting 1-year outcome post-LT (COSSH-ACLFs/CLIF-C ACLFs/MELDs/MELD-Nas: AUROC 0.835/0.825/0.796/0.781; all p < 0.05). The C-indexes confirmed the high predictive value of COSSH-ACLF IIs. Survival benefit rate analyses showed that patients with COSSH-ACLF IIs 7–10 had a higher 1-year survival benefit rate from LT (39.2%–64.3%) than those with score <7 or >10. These results were prospectively validated. INTERPRETATION: COSSH-ACLF IIs identified the risk of death on the waitlist and accurately predicted post-LT mortality and survival benefit for HBV-ACLF. Patients with COSSH-ACLF IIs 7–10 derived a higher net survival benefit from LT. FUNDING: This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (No. 81830073, No. 81771196) and the National Special Support Program for High-Level Personnel Recruitment (Ten-thousand Talents Program). |
format | Online Article Text |
id | pubmed-9923183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99231832023-02-14 Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study Li, Peng Liang, Xi Luo, Jinjin Li, Jiaqi Xin, Jiaojiao Jiang, Jing Shi, Dongyan Lu, Yingyan Hassan, Hozeifa Mohamed Zhou, Qian Hao, Shaorui Zhang, Huafen Wu, Tianzhou Li, Tan Yao, Heng Ren, Keke Guo, Beibei Zhou, Xingping Chen, Jiaxian He, Lulu Yang, Hui Hu, Wen Ma, Shiwen Li, Bingqi You, Shaoli Xin, Shaojie Chen, Yu Li, Jun Lancet Reg Health West Pac Articles BACKGROUND: Liver transplantation (LT) is an effective therapy for acute-on-chronic liver failure (ACLF) but is limited by organ shortages. We aimed to identify an appropriate score for predicting the survival benefit of LT in HBV-related ACLF patients. METHODS: Hospitalized patients with acute deterioration of HBV-related chronic liver disease (n = 4577) from the Chinese Group on the Study of Severe Hepatitis B (COSSH) open cohort were enrolled to evaluate the performance of five commonly used scores for predicting the prognosis and transplant survival benefit. The survival benefit rate was calculated to reflect the extended rate of the expected lifetime with vs. without LT. FINDINGS: In total, 368 HBV-ACLF patients received LT. They showed significantly higher 1-year survival than those on the waitlist in both the entire HBV-ACLF cohort (77.2%/52.3%, p < 0.001) and the propensity score matching cohort (77.2%/27.6%, p < 0.001). The area under the receiver operating characteristic curve (AUROC) showed that the COSSH-ACLF II score performed best (AUROC 0.849) at identifying the 1-year risk of death on the waitlist and best (AUROC 0.864) at predicting 1-year outcome post-LT (COSSH-ACLFs/CLIF-C ACLFs/MELDs/MELD-Nas: AUROC 0.835/0.825/0.796/0.781; all p < 0.05). The C-indexes confirmed the high predictive value of COSSH-ACLF IIs. Survival benefit rate analyses showed that patients with COSSH-ACLF IIs 7–10 had a higher 1-year survival benefit rate from LT (39.2%–64.3%) than those with score <7 or >10. These results were prospectively validated. INTERPRETATION: COSSH-ACLF IIs identified the risk of death on the waitlist and accurately predicted post-LT mortality and survival benefit for HBV-ACLF. Patients with COSSH-ACLF IIs 7–10 derived a higher net survival benefit from LT. FUNDING: This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (No. 81830073, No. 81771196) and the National Special Support Program for High-Level Personnel Recruitment (Ten-thousand Talents Program). Elsevier 2022-11-10 /pmc/articles/PMC9923183/ /pubmed/36793753 http://dx.doi.org/10.1016/j.lanwpc.2022.100638 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Li, Peng Liang, Xi Luo, Jinjin Li, Jiaqi Xin, Jiaojiao Jiang, Jing Shi, Dongyan Lu, Yingyan Hassan, Hozeifa Mohamed Zhou, Qian Hao, Shaorui Zhang, Huafen Wu, Tianzhou Li, Tan Yao, Heng Ren, Keke Guo, Beibei Zhou, Xingping Chen, Jiaxian He, Lulu Yang, Hui Hu, Wen Ma, Shiwen Li, Bingqi You, Shaoli Xin, Shaojie Chen, Yu Li, Jun Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study |
title | Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study |
title_full | Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study |
title_fullStr | Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study |
title_full_unstemmed | Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study |
title_short | Predicting the survival benefit of liver transplantation in HBV-related acute-on-chronic liver failure: an observational cohort study |
title_sort | predicting the survival benefit of liver transplantation in hbv-related acute-on-chronic liver failure: an observational cohort study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923183/ https://www.ncbi.nlm.nih.gov/pubmed/36793753 http://dx.doi.org/10.1016/j.lanwpc.2022.100638 |
work_keys_str_mv | AT lipeng predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT liangxi predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT luojinjin predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT lijiaqi predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT xinjiaojiao predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT jiangjing predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT shidongyan predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT luyingyan predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT hassanhozeifamohamed predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT zhouqian predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT haoshaorui predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT zhanghuafen predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT wutianzhou predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT litan predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT yaoheng predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT renkeke predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT guobeibei predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT zhouxingping predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT chenjiaxian predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT helulu predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT yanghui predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT huwen predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT mashiwen predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT libingqi predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT youshaoli predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT xinshaojie predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT chenyu predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT lijun predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy AT predictingthesurvivalbenefitoflivertransplantationinhbvrelatedacuteonchronicliverfailureanobservationalcohortstudy |